SUO 2019 bipolar androgen therapy (BAT) for men with castration-resistant prostate cancer, Samuel Denmeade, three phases of androgen inhibition: shock, adaptation, and resistance, TRANSFORMER phase II trial.
AUA 2025 ARANOTE trial (NCT04736199), ad hoc analysis of the phase III ARANOTE trial, efficacy and safety of darolutamide + ADT in black patients with…
AUA 2025 State-of-the-Art Lecture on Urothelial Markers, biomarkers for urothelial cancer, Tissue based biomarkers, RETAIN-2 trial, membranous Nectin-4 in urothelial cancer, CxBladder.
AUA 2025, Metastatic Renal Cell Carcinoma (mRCC), Upfront Cytoreductive Nephrectom, Upfront Cytoreductive Nephrectomy With Deferred Systemic Therapy For Metastatic Renal Cell Carcinoma, CARMENA trial,
AUA 2025 performance of minimal residual disease detection with urine-derived DNA, high-grade bladder cancer, recommended repeat TURBT, UroAmp.
AUA 2025, prostate cancer, 18F-DCFPyL, 18F-FDG PET/CT, Heterogeneity of Advanced Prostate Cancer by 18F-DCFPyL and 18F-FDG PET/CT, dual-tracer (¹⁸F-DCFPyL and ¹⁸F-FDG) PET/CT imaging.
AUA 2025, upper tract urothelial carcinoma (UTUC), Tislelizumab, humanized IgG4 anti-PD-1 monoclonal antibody.
AUA 2025, kidney cancer, renal cell carcinoma (RCC), metastatic renal cell carcinoma (mRCC), Nivolumab, Ipilimumab, Nivolumab plus Ipilimumab Therapy, sunitinib, Primary Resistance to Nivolumab plus…
AUA 2025 KEYNOTE-564 trial, clear cell renal cell carcinoma (ccRCC), adjuvant pembrolizumab, partial nephrectomy,
AUA 2025 PSMA-PET imaging to stage men with prostate cancer, regional lymph node involvement, distant metastases, preoperative PSMA-PET imaging, Michigan Urological Surgery Improvement Collaborative (MUSIC),
AUA 2025, Prostate Cancer, Prostate Cancer Risk Groups by PSMA-PET PROMISE (PPP), Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography (PSMA-PET), PROMISE registry.
